Background: Preoperative chemoradiotherapy followed by surgical mesorectal resection is the standard of care for locally advanced rectal carcinomas. Yet, predicting that patients will respond to treatment remains an unmet clinical challenge.
Introduction
Chemoradiotherapy (CRT) and surgical mesorectal resection is the standard of care for patients with locally advanced carcinoma of the rectum (LARC) [1] . After numerous randomized trials, it is now clear that, compared with postoperative adjuvant CRT, preoperative CRT followed by adjuvant chemotherapy yields significantly lower local recurrence rates, less acute and long-term toxicity and enables a higher rate of sphincter-saving surgery, thereby improving patient quality of life and disease-free survival [2] . However, it is still difficult to predict which patients will achieve complete or almost complete response (as is the case for around 40% of them; tumour regression grade TRG 1 and 2 according to Mandard's score) and which will develop intrinsic or acquired resistance during the treatment period [3] . Therefore, it is crucial to identify patients who will not respond to treatment in order to avoid unnecessary toxicities, and to bring forward scheduled surgical treatment or, eventually, offer alternative treatment options.
Some single biomarkers have been reported for response prediction in LARC [4, 5] but to date none has been consistently validated. Also approaches using profiling expression [6] [7] [8] with no gene overlap among these studies.
On the other hand, the relevance of the stroma as one of the most significant contributor to colorectal cancer prognosis has recently been recognized [9, 10] .
With respect to the predictive capacities of the stroma, in 2009, Farmer et al. showed that the stroma potentially supplies biomarkers for selecting oestrogen receptor-negative breast cancer patients who will respond to preoperative chemotherapy based on 5-fluorouracil, epirubicin and cyclophosphamide [11] . They showed that the composition of the stroma, rather than the quantity, might be fundamental to the hampering of the response to chemotherapy, as we had previously suggested for prognosis [12] .
Here, we explore how differential stromal transcriptomic profiles between responder and non-responder LARC patients before preoperative treatment can be used to define an immunohistochemical score based on two CAF-specific proteins for predicting neoadjuvant treatment response from endoscopic diagnostic biopsies.
Methods Samples
We prospectively obtained pretreatment endoscopic biopsies from 15 rectal cancer patients candidates for preoperative CRT treatment. Biopsies consisted in 5-to-8 small tumour pieces, representing tumour heterogeneity. Samples were obtained with the approval of the Ethics Committee of the Hospital Universitari de Bellvitge (IDIBELL). Once the signed informed consent of the patients had been obtained, fresh samples were embedded in OCT compound, sectioned and stained using an Arcturus Histogene LCM Frozen Section kit. Stroma and tumour were microdissected ($3-4 Â 10 6 lm 2 ) using an Arcturus XT microscope. After preoperative treatment we assessed the pathological response, using Mandard's classification [13] : TRG1 (pathologically complete response), TRG2 (scattered tumour cells), TRG3 (partial response with preponderance of fibrosis), TRG4 (partial response with preponderance of tumour cells) and TRG5 (no changes of regression). TRG1 and TRG2 were considered to be responders and TRG3, TRG4 and TRG5 were classified as non-responders.
Microarray analysis and probe filtering
Detailed information on microarray analysis and probe filtering is described in supplementary Methods, available at Annals of Oncology online.
Immunohistochemistry
Candidate probes/genes (those with slope > 1; see above) were validated by immunohistochemical staining. MMP2, fibronectin 1, collagen 1, collagen 3A1 and IGFBP5 were evaluated in the stroma (detailed information in supplementary Methods, available at Annals of Oncology online). Staining intensity for all antibodies was graded as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong); extension was graded as 0 (0%-5%), 1 (6%-25%), 2 (26%-50%), 3 (51%-75%) or 4 (>75%), percentages of stained stroma. A semi-quantitative score for each antibody was obtained by multiplying intensity Â extension, yielding scores between 0 and 12 points. The immunoscores for each sample will be used for creating generalised regression models.
Patient samples for developing the protein classifier
We obtained retrospective FFPE pretreatment endoscopic biopsies (5-to-8 small tumour pieces; independent samples from those used in the microarray analysis) from two consecutive LARC cohorts of 38 patients (training series) and 36 patients (validation series) from the Pathology Department of the Hospital de Bellvitge (L'Hospitalet de Llobregat, Barcelona, Spain). All patients received homogeneous neoadjuvant treatment consisting of radiotherapy and chemotherapy (oxaliplatin plus fluoropyrimidines). Corresponding postoperative surgical specimens were graded from TRG1 to TRG5. The baseline information for each cohort is summarised in Table 1 .
The study samples were assembled after approval by the Ethics Committee of our institution. Signed, informed consent was obtained from each patient. The study was conducted in accordance with the REMARK guidelines for the development of prognostic and predictive biomarkers [14] .
We calculated a risk score for each patient in the training series based on the immunoreactive scores of the covariates (intensity Â extension), weighted by the regression coefficients obtained by means of a generalized linear regression model L1 penalised using a leave-one-out cross validation (LOOCV). As a cut-off we used the highest score observed in responder's patients (training set). We applied the model and the cut-off generated in the training series to the validation series.
Tumour-stroma ratio assessment
The tumour-stroma ratio was assessed as previously described [12, 15] , detailed in supplementary Methods, available at Annals of Oncology online.
Results
The stroma contributes with the vast majority of changes in gene expression between responders and non-responders
To explain the differential behaviour of responders (TRG1, TRG2) and non-responders (TRG3, TRG4 and TRG5) we obtained the gene expression profile of tumour stroma and tumour glands separately from endoscopic biopsies before preoperative treatment using a laser-capture microscope. As detailed in the SAM plots (supplementary Figure S1A , available at Annals of Oncology online), almost no differences were observed between tumour cells of non-responders and responders, while the stroma displayed a massive transcriptomic change. Detailed analysis is described in supplementary Results, available at Annals of Oncology online. Expression profiles of genes with statistically significant differences between responders and non-responders were explored by unsupervised sample-based cluster analysis.
Hierarchical clustering clearly separated the outcomes (supplementary Figure S1B , available at Annals of Oncology online). A detailed functional annotation and gene set enrichment analysis is detailed in supplementary material (supplementary Results and Figure S2 , available at Annals of Oncology online).
Building a CAF-specific IHC classifier for response prediction
In order to move from transcriptomic data to the protein level, we filtered those genes with the greatest probabilities of being validated by means of IHC staining, given the limitations of the technique for discriminating small variations in protein expression in comparison to mRNA approaches. We ran a linear regression including all the DEGs to identify those that were associated with monotonic increases from TRG5 to TRG1 samples and vice versa ( Figure 1A ). We filtered genes with a regression coefficient >1 or <-1 for further analysis; these are the ones that yield the biggest monotonic increases or decreases in expression (supplementary Results, available at Annals of Oncology online). We used GSE39396 to define cell-type specificity of filtered best candidate genes. As depicted in Figure 1B , the CAF-specific genes among those with the highest slope coefficients are FN1, COL3A1, COL1A1, MMP2 and IGFBP5.
We evaluated the immunohistochemical staining of fibronectin, collagen 3A1, collagen 1A1, MMP2 and IGFBP5 in a series of 38 pretreatment rectal biopsies. Endoscopic biopsies consist in 5-to-8 small pieces of tumour tissue, capturing different parts from the same tumour. We scored each sample from 0 (minimum) to 12 (maximum) for staining intensity and extension, as detailed in the Materials and methods section.
For predictive purposes we used LOOCV GLMNET regression analysis to derive a cross-validated model using the five proteins for predicting response to neoadjuvant treatment. As shown in Figure 1C , for cross-validated probabilities of the training cohort, the classifier has a reasonable performance detailed in Table 2 .
Classifier refinement
In order to improve classification and to reduce the number of proteins to be evaluated, we used random forest machine learning to rank the relevance of the five proteins with respect to the capacity to discriminate between responder and non-responder patients.
As depicted in Figure 1D , the mean decrease in the Gini index clearly shows that fibronectin 1 (FN1) is the strongest predictor (ANOVA, P < 2 Â 10
216
). The predictor COL3A1 also carried out well compared with MMP2, IGFBP5 and COL1A1, with a significantly greater mean decrease in the Gini index (T-test, P < 2.2 Â 10 216 ). Therefore, we reconsidered the LOOCV GLMNET model including only FN1 and COL3A1 as covariates, and derived a formula to calculate a risk score using the regression coefficients as weights for each marker: risk score
.026 (regression intercept). Then, we calculated the cross-validated probabilities of assignment to the high and low risk of non-response groups, depicted in Figure 1E (training series). The two-protein regression model clearly carried out better than the five-protein classifier with the same dataset, as illustrated in Table 2 , improving the positive predictive value (PPV) from 83.3% to 93.3%.
Additionally, tumours with a high two-protein score (high risk of non-response) were significantly associated with the TRG (v 2 test, P ¼ 0.00035) and pathological stage yPN (P ¼ 0.048) and a trend for yPT (P ¼ 0.063; Table 3 ).
The two-protein classifier is a strong predictor of treatment response in an independent cohort of LARC We used a second cohort of 36 pretreatment endoscopic biopsy samples from LARC patients to validate the effectiveness of the GSM967347  GSM967339  GSM967359  GSM967343  GSM967351  GSM967355  GSM967340  GSM967344  GSM967362  GSM967348  GSM967352  GSM967356  GSM967341  GSM967345  GSM967353  GSM967349  GSM967361  GSM967357  GSM967350  GSM967346  GSM967342  GSM967354  GSM967358 cross-validated two-protein predictive classifier obtained in the first cohort. As depicted in Figure 1F , the FN1-COL3A1 immunohistochemical score carried out well according to the ROC curve (AUC ¼ 0.894, 95% CI ¼ 0.79-0.89). Immunoscores of responder's patients were statistically lower than those of the nonresponder's patients ( Figure 1G ). We applied the cross-validated maximal responder's score obtained in the training cohort to dichotomise the samples of the second cohort with respect to the risk of non-response to the neoadjuvant treatment ( Figure 1H ). As a dichotomised variable, the clinical utility of the two-stromal protein classifier had a PPV of 88.2% and a positive weighted Likelihood ratio of 7.5 ( Table 2 ). In addition, tumours with a high two-protein score were statistically associated in the validation cohort with TRG (v 2 test, P ¼ 0.001), pathological stage yPT (P ¼ 0.021), the mean and dichotomised pre-treatment CEA (P ¼ 0.016 and P ¼ 0.008, respectively) but not with clinical stage or the tumour/stroma ratio (Table 3 ; Figures 1I, 2A and B and supplementary Figure S3 , available at Annals of Oncology online). In addition tumour/ stroma ratio was also not associated with the true response (responders, 53.3% high stroma, 46.7% low stroma; nonresponders, 42.9% high stroma, 57.1% low stroma; P ¼ 0.53).
The two-protein risk score proved to be the only independent predictor of response to the neoadjuvant treatment (odds ratio OR ¼ 2.51 per unit of increase of the score, 95% CI ¼ 1.3-4.77, P ¼ 0.006; Table 4 ) in a multivariate logistic regression analysis.
Discussion
The standard treatment of LARC is preoperative CRT, since this avoids the undesirable level of uncertainty surrounding nonoptimal free-margin surgery, followed by adjuvant treatment. There is also a general concern amongst oncologists about the need to avoid overtreating some patients. Thus, there is a need to identify biomarkers that can help us accurately select patients who would not respond to current standard preoperative treatment, with few false positives. In the meantime, patients are still selected for neoadjuvant treatment largely on the basis of the preoperative clinical stage determined by imaging techniques such as MRI, ultrasonography or PET/TC, while the capacity to predict their response has not been demonstrated. In addition, no biomarker has so far been applied that has sufficient accuracy to warrant a change in current clinical guidelines [16] .
The cancer-associated stroma has been established as being one of the most significant contributors to the outcome of colorectal cancer [9, 10] . However, although stromal gene expression profiling has been used to predict the outcome of various cancer types [15, 17] , no studies have so far reported its use to predict the response to CRT using preoperative biopsies for LARC. In fact, in our transcriptomic analysis of laser-capture microdissected samples, still naïf to any treatment, almost no differences in the epithelial cancer cells were noted between responder and non-responder patients. The stroma compartment displayed a importance showing the mean decrease in the Gini coefficient for the five proteins. The random forest (RF) machine learning method was used in R (randomforest package, 4.6-12) using the default options. The training set consisted of two-thirds of the sample, randomly sampled for each decision tree in the RF. For validation, RF decision trees were analysed for accuracy in patients who did not contribute to the definition of these trees ('out-of-bag' predictions). As a measure of the predictor's contribution to the correct samples classification we measured the mean decrease in the GINI coefficient for all the predictions. The graph shows that FN1 (fibronectin 1) and COL3A1 (collagen 3) are clearly the two best predictors. T-tests were used to compare COL3A1 with COL1A1, MMP2 or IGFBP5 (P<2.2Â10
À16
, for all pairs). (E) Scatterplot of leave-one-out cross-validated (LOOCV) probabilities from the generalized linear model for the two-protein classifier in the training series. The red dotted line represents the probability of the LOOCV, with the cross-validated maximal responder immunoscore, used as the cutoff. (F) Receiver-operating characteristic curve showing the performance of the two-protein classifier in the independent validation series. (G) Box-plot of the two-protein classifier scores for the 36 patients in the validation cohort according to the true pathological response. The true response statuses were dichotomized as 'responder' for patients with Mandard's tumour regression grade 1 and 2, or 'non-responder' for grades 3, 4 or 5. (T-student P¼0.000012; the red dotted line represents the maximal immunoscore value of responder patients in the training set. (H) scatter-plot of the probabilities of the 36 patients after applying the LOOCV model obtained from the training series. We calculated a risk score for each patient in the validation series based on the immunoreactive scores of the covariates, weighted by the regression coefficients obtained in the training series and assigning patients to high-or low-risk groups according to the maximal responder's immunoscore, also obtained from the training series. Most non-responder patients would benefit from an advancement of scheduled surgery; misclassified non-responders would be treated anyway according to current clinical guidelines. (I) Scatter-plot of the two-protein classifier score of the 36 patients in the validation cohort according to the tumour/stroma ratio. Black and grey circles indicate tumours with a low ( 50%) and high (!55%) percentage of stroma, respectively (detailed information of the assessment in the supplementary Methods, available at Annals of Oncology online). very different transcriptomic profile, also highlighting the role of the stroma as a significant contributor to treatment response. In this paper, we report the development and validation of an immunohistochemical score based on the assessment of only two stromal proteins (fibronectin and collagen 3A1) derived from DEGs from microdissected pretreatment endoscopic biopsies from rectal cancer. Such biopsies consist in different parts of the same tumour, therefore capturing tumour heterogeneity. The Figure 2 . (A) Microphotographs (Â100 and Â400) of histochemical (HÀE) and immunohistochemical staining of aSMA, fibronectin and collagen 3 of representative cases of high-stroma aSMA enriched areas of responder and non-responder patients, showing the greater intensity and extension in non-responder patients for both Fibronectin 1 and Collagen 3A1. Responder patient was categorised as stroma-high, Fibronectin ¼ intensity 2 Â extension 3, Collagen3A1 ¼ intensity 1 Â extension 1; non-responder patient was categorised as stroma-high, Fibronectin ¼ intensity 3 Â extension 4, Collagen3A1 ¼ intensity 2 Â extension 4. Additional images are available in supplementary Figure S3 , available at Annals of Oncology online. (B) Box-plot of the risk score according to the tumour/stroma ratio (t-student, P ¼ 0.71; high stroma > 55% stroma extension; low stroma 50 stroma extension, evaluated in 5-to-8 different tumour pieces).
two-protein classifier, based on a highly amenable technique, was associated with a prediction of non-response to the neoadjuvant treatment in LARC with high accuracy. The high PPV makes the classifier useful for clinical decision making, whereby unnecessary toxicities associated with neoadjuvant treatment may be avoided and by which patients with a very low probability of response, scheduled surgery might be brought forward or even offering them alternative treatment. The multivariate analysis showed that the two-protein classifier, as a continuous variable, is an independent predictive factor that increases the risk of nonresponse 2.51-fold per unit increase in the two-protein score.
Choosing the right cut-off for a test designed to identify nonresponder patients is crucial when employing the standard neoadjuvant treatment of resectable cancer patients. On one hand, it is not desirable to treat patients who will not respond (false negatives), even though current guidelines would lead them to be treated anyway. On the other hand, it is very important to minimise false positives (not treated responders), since they will face more complicated but potentially curative advanced scheduled surgery with lower chances of free-margin resection and sphincter preservation plus adjuvancy. For our protein classifier, we decided to use the maximal immunoscore observed in the responder patients of the training cohort, instead of a statistically determined data-driven cut-offs. This approach produced few false positives, an acceptable level of false negatives (patients who would have been treated anyway) and a rather significant clinical utility.
While the quantity of stroma has been associated with poor survival in different cancer types [15, 17] and particularly defining the colorectal subtype with worst prognosis [18] , the stromal two-protein IHC classifier carried out well regardless of the stroma ratio in the tumour specimen, indicating that the composition/expression pattern of such stroma, rather than solely the quantity, is very important for exerting the protective role of the tumour cells against therapies. In fact, some colorectal tumours classified as good-prognosis subtype (CMS1, 2 or 3), displaying moderate levels of stroma but expressing a particular CAF gene cluster, exhibit the same high-risk of relapse as CMS4 tumours [9] . This is largely due to the great heterogeneity in the stroma, and CAF population in particular, with some being tumoursuppressive and some protumourigenic [19] which is ultimately reflected in the very different composition of the extracellular matrix. The balance between such subpopulations might be relevant for prognosis but is actually determinant for drug response. In fact a virtual microdissection in PDAC demonstrated the coexistence of CAFs with different transcriptomic patterns, being associated such patterns with prognosis [19] . Moreover, these transcriptomic programmes conferring bad prognosis had been determined in CAFs in different cancer types [20] . Interestingly, there is a high level of overlap between our signature of non-responder's stromal genes and the pan-cancer gene signature of poor prognosis CAFs.
In conclusion, in this study we developed a two-protein classifier based on the immunoscoring of fibronectin 1 and collagen 3A1 that carried out well in predicting the absence of response to neoadjuvant treatment in LARC. Although further prospective studies in bigger cohorts are needed to validate the utility of the classifier, our approach reinforces the value of the stroma as a source of predictive biomarkers. For multivariate analysis, binary logistic regression was applied using the two-protein classifier as a continuous variable, as well as clinical stage, age below 60 years old, gender, pre-treatment CEA above 5 ng/ml and the stroma ratio (!55%) as covariates. We reported odds ratio (OR) and its 95% confidence interval.
